First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.

doi:10.1097/JTO.0b013e318260de8b

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2012

Maemondo Makoto, Minegishi Yuji, Inoue Akira, Kobayashi Kunihiko, Harada Masao, Okinaga Shoji, Morikawa Naoto, Oizumi Satoshi, Tanaka Tomoaki, Isobe Hiroshi, Kudoh Shoji, Hagiwara Koichi, Nukiwa Toshihiro, Gemma Akihiko, Gemmah Akihiko

Abstract excerpt

INTRODUCTION: Recent studies have demonstrated that first-line treatment with gefitinib, an epidermal growth factor receptor (EFGR)-targeted tyrosine kinase inhibitor, is significantly superior to standard chemotherapy for advanced non-small-cell lung cancer (NSCLC) harboring EGFR sensitive mutations. Meanwhile, the efficacy of gefitinib therapy among elderly populations diagnosed with EGFR-mutated NSCLC has not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Adenosquamous

Share to Carcinoma, Non-Small-Cell Lung

Share to Feasibility Studies

Share to Gefitinib

Share to Neoplasm Staging

Share to Quinazolines

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 22895139
DOI: 10.1097/JTO.0b013e318260de8b

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.PMID 22895139Read ↗

First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.Semantic proximity Read ↗

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.Semantic proximity Read ↗

Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.Semantic proximity Read ↗

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.Semantic proximity Read ↗

First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901Semantic proximity Read ↗

First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.Semantic proximity Read ↗

Gefitinib for non-small-cell lung cancer treatment.Semantic proximity Read ↗

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).Semantic proximity Read ↗

Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.Semantic proximity Read ↗

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.